[Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis].
Multiple sclerosis (MS) has traditionally been considered to be a T cell-mediated disease. However, there is an increasing body of evidence for the involvement of B cells and autoantibodies in the pathology of this disease, providing a rationale for treatment strategies directed against B cells. This paper summarizes the evidence for a key role of B cells in the immunopathology of MS and reviews data supporting the use of a novel B cell-targeted therapy, atacicept, for this condition. Atacicept is a human recombinant fusion protein that comprises the binding portion of a receptor for both BLyS (B Lymphocyte Stimulator) and APRIL (A PRoliferation-Inducing Ligand), two cytokines that have been identified as important regulators of B cell maturation, function and survival. Atacicept has shown selective effects on cells of the B cell lineage, acting on mature B cells and blocking plasma cells and late stages of B cell development while sparing B cell progenitors and memory cells. The efficacy of atacicept in animal models of autoimmune disease and the biological activity of atacicept in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) has been demonstrated. Ongoing clinical studies are investigating the safety, tolerability and efficacy of atacicept in patients with MS, SLE and RA.
Hartung
H-P
HP
Neurologische Klinik, Heinrich-Heine-Universität, Moorenstrasse 5, Düsseldorf. hans-peter.hartung@uni-duesseldorf.de
D001402:B-Lymphocytes / Q000187:drug effects*; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems / Q000379:methods*; D019317:Evidence-Based Medicine / Q000639:trends*; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D016896:Treatment Outcome
D011993:Recombinant Fusion Proteins; C524618:TACI receptor-IgG Fc fragment fusion protein